Search results

Selected filters:

Litigation

Article type

Topic

Sector

Regions

3,172 results found for your search

Sort options
07 December 2018

Any attempts at 101 reform must deal with a Silicon Valley sized problem

Closed door meeting on Capitol Hill looks to set the agenda for patent legislation in next Congress

04 December 2018

IPBC Asia Day Two report

This year's event in Shanghai has now come to an end. It's been a great couple of days, including the IP Asia Elite Gala Dinner and Awards held last night

04 December 2018

New lawsuits against AT&T, Sprint and Verizon suggest ETRI is doubling down on US monetisation strategy

After setback in Huawei suit, latest court cases show the state-funded Korean research institute is behind massive licensing programme

03 December 2018

IPBC Asia 2018 Day One Report

How Chinese courts will rule the patent world; Qualcomm's 5G licensing spree; don't jail trolls, says former supreme court judge; patent sales are on the up; plus a whole lot more from a wet, but spectacular, Shanghai Pudong

02 December 2018

Weekly review - 26th November to 2nd December

Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one

01 December 2018

The 2018 brokered patent market

“The patent market has fully stabilised and prices are rational,” said no one ever. During 2018 total dollars transacted in brokered deals increased while prices of single-asset deals have dropped significantly.

30 November 2018

A director’s guide to modernising IP governance frameworks

Boards and directors typically prioritise non-IP issues on the corporate agenda; however, legal requirements and market activities suggest that this might be a serious misstep.

30 November 2018

How a Chinese court would have answered the three questions in the Unwired Planet appeal

Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions 

30 November 2018

Time is running out to nominate the world’s leading IP strategists

There is not much time left to make nominations for the 2019 edition of IAM Strategy 300, our exclusive guide on the world's best IP strategists.

30 November 2018

Patents, platform technologies and new therapeutic modalities

The pace of change in the life sciences industry is startling and is putting traditional IP management strategies under extreme pressure. It may be time for IP leaders to start looking to the tech industry experience for lessons in how to respond.

30 November 2018

After years of setting the patent agenda Silicon Valley is now playing defence

The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative.

30 November 2018

Local players make case for Brazil as monetisation hub although spectre of huge patent backlog looms large

Inaugural IPBC Latin America throws spotlight on untapped potential of region’s largest economy although Volkswagen’s long wait for grants underline challenges that rights owner face in country

30 November 2018

Why the EPO should decide which SEPs are essential

The heads of intellectual property at Swedish automaker Volvo Car Corporation and Swiss wireless communications supplier u-blox AG believe that the EPO must play a central role in deciding on mobile technology SEPs.

30 November 2018

US pharma patents are under greater threat than ever before

Life sciences companies in the United States are under increasing pressure. Campaigners for changes to the patent system are working to prevent what they see as abusive practices – and it looks as if they are winning the argument.

30 November 2018

Continuation patent assertion in the US may be tougher after CAFC decision

First application of the court’s SimpleAir standard led to a 45% slump in Invidior’s share price and could prove to be a boon for generics companies